ScreenerHero

ILMN Illumina, Inc.

NAS · US · Healthcare · Diagnostics & Research · illumina.com
293.69USD+7.56%Mkt Cap: 44.35B $P/E: 54.79

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and arr…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
GH
Guardant Health, Inc.
$25.12BUSD
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
CRL
Charles River Laboratories International, Inc.
$14.84BUSD
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2
GRAL
GRAIL, Inc.
$6.88BUSD

Key Statistics

Company
Market Cap44.35B USD
Enterprise Value42.59B USD
Revenue (TTM)4.49B USD
Gross Profit2.87B USD
Net Income (TTM)850.00M USD
Revenue/Share29.57 USD
Last Price293.69 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8.6K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)54.79
P/E (Forward)44.72
PEG3.37
EV/EBITDA36.87
EV/Revenue9.48
P/S9.17
P/B14.53
EPS (TTM)5.36
EPS (Forward)6.11
52W Range
88.0099% of range296.25
52W High296.25 USD
52W Low88.00 USD
Profitability
Gross Margin66.08%
Oper. Margin21.14%
EBITDA Margin25.70%
Profit Margin19.57%
ROE31.22%
ROA12.79%
Growth
Revenue Growth9.40%
Earnings Growth-9.40%
Cash Flow & Leverage
Operating CF1.08B USD
CapEx (TTM)148.00M USD
FCF Margin17.75%
FCF Yield1.80%
Net Debt1.36B USD
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity0.94
Current Ratio1.80
Quick Ratio1.25
Book Value/Sh18.80 USD
Cash/Share7.74 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1028:1000
Split DateJun 25, 2024
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)214.60 USD
Upside (mean)-26.9%
Target Range113.00 USD – 305.00 USD
113.00-26.9% to mean305.00
# Analysts20
Ownership
Shares Out.151.00M
Float149.78M
Insiders0.21%
Institutions106.25%
Short Interest
Short Ratio5.5d
Short % Float11.47%
Short % Out.7.01%
Shares Short10.59M
Short (prev mo.)9.46M
Technical
SMA 50218.89 (+34.2%)
SMA 200162.70 (+80.5%)
Beta1.47
S&P 52W Chg14.58%
Avg Vol (30d)3.26M
Avg Vol (10d)2.96M
Technical Indicators
RSI (14)77.6
MACD19.9301
MACD Signal16.6592
MACD Hist.+3.2708
BB Upper302.73 USD
BB Middle243.80 USD
BB Lower184.87 USD
BB Width48.35%
ATR (14)12.10 USD
Vol Ratio (20d)1.05x